Eur Heart J Card Pharm:长期使用布洛芬增加31%心脏骤停风险

2017-03-20 卢芳 中国循环杂志

非甾体类消炎镇痛药,是药店常见的药物了,但近期发表在European Heart Journal子刊上的一项来自丹麦的研究警示,这些药物增加心脏骤停风险。



非甾体类消炎镇痛药,是药店常见的药物了,但近期发表在European Heart Journal子刊上的一项来自丹麦的研究警示,这些药物增加心脏骤停风险。

研究显示,使用非甾体消炎药会增加31%的心脏骤停风险,其中最常用的双氯芬酸增加50%的风险,布洛芬增加31%的风险。其他如萘普生、塞来昔布和罗非考昔未发现与心脏骤停相关,但研究者认为,可能因为应用少、事件发生率少有关。

据介绍,非甾体类消炎药可从多方面影响心血管系统,比如促成血栓形成、血管收缩,增加液体潴留以及升高血压等。

研究者建议,因尽量避免使用双氯芬酸,布洛芬每日用量也不要超过1200 mg。此外,萘普生或许较为安全,可以每日服用500 mg。

“这些消炎止痛药,通常无需处方在药店就可购到,公众也常常认为很安全。但我们研究显示这些药物并非无害,尤其是常用的双氯芬酸和布洛芬。公众应该慎重应用这些药物,尤其对于那些有心血管病或伴有多种心血管危险因素者应避免使用。”研究者表示。

研究者分析了2001-2010年丹麦28947例院外心脏骤停患者,有3376人在心脏骤停前应用非甾体类消炎药达30天。布洛芬和双氯芬酸是最常用的药物,分别占51%和22%。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787222, encodeId=96cd1e872223b, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Feb 23 10:16:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010137, encodeId=cc94201013e8e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Jul 04 09:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356199, encodeId=02ac1356199d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562464, encodeId=caa3156246447, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=)]
    2018-02-23 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787222, encodeId=96cd1e872223b, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Feb 23 10:16:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010137, encodeId=cc94201013e8e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Jul 04 09:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356199, encodeId=02ac1356199d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562464, encodeId=caa3156246447, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787222, encodeId=96cd1e872223b, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Feb 23 10:16:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010137, encodeId=cc94201013e8e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Jul 04 09:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356199, encodeId=02ac1356199d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562464, encodeId=caa3156246447, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=)]
    2017-03-22 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787222, encodeId=96cd1e872223b, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Fri Feb 23 10:16:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010137, encodeId=cc94201013e8e, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Tue Jul 04 09:16:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356199, encodeId=02ac1356199d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562464, encodeId=caa3156246447, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Mar 22 01:16:00 CST 2017, time=2017-03-22, status=1, ipAttribution=)]
    2017-03-22 slcumt

相关资讯

第三代非甾体MR拮抗剂finerenone对慢性心力衰竭和糖尿病性肾病进入III期临床试验阶段

德国制药巨头拜耳(Bayer)近日宣布,将启动新型口服非甾体盐皮质激素受体拮抗剂(MRA)finerenone(BAY 94-8862)的III期临床开发项目,计划开展3个III期临床研究,调查finerenone治疗慢性心脏衰竭(CHF)和糖尿病性肾病(DKC)的疗效和安全性。首批患者预计将在2015年底招募。此次III期项目的启动,是基于在CHF和DKD中开展的4个剂量探索研究。 近年来,尽